gene therapy, Regeneron Pharmaceuticals and deafness

Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one-time treatment.
Regeneron gene therapy helps deaf children hear in small study
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s treatment, new data show.
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a mutation to the otoferlin gene. The company snapped up DB-OTO through its $109 million acquisition of Decibel Therapeutics in 2023.
Regeneron’s Gene Therapy Restores Hearing in Patients with Rare Genetic Deafness
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.
Regeneron reports positive results for deafness therapy
Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment of profound genetic hearing loss in children due to certain variants of the OTOF gene.
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
JD Supra46m
The First Circuit Has Held That the “But-For” Causation Standard Is Appropriate for Anti-Kickback Statute–Based False Claims Act Allegations
Our Health Care Group discusses a First Circuit case holding that could have a significant impact in establishing “but-for” causation as the ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains
This was the stock's fifth consecutive day of gains.
US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
JD Supra1h
First Circuit Adopts “But For” Causation Standard under the Anti-Kickback Statute, Paving the Way for Potential Supreme Court Review
Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals with ...
Regeneron announces updated DB-OTO data from CHORD trial
Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...